title: Efficacy and safety of single-triple capsules of bismuth biskalcitrate, metronidazole and tetracycline, given with omeprazole, for the eradication of Helicobacter pylori: an international multicentre study.
abstract: BACKGROUND
  The high prevalence of Helicobacter pylori resistance to metronidazole demands treatments more effective than standard bismuth-based triple therapy against these strains.
  
  
  OBJECTIVE
  To evaluate the H. pylori eradication rate in both metronidazole-sensitive and -resistant strains following quadruple therapy using single-triple capsules of bismuth biskalcitrate, metronidazole and tetracycline, given with omeprazole.
  
  
  METHODS
  One hundred and seventy valid patients with duodenal ulcer, gastric ulcer or non-ulcer dyspepsia were treated in eight centres located in five countries. H. pylori was confirmed at baseline using 13C-urea breath test, histology and/or culture. Patients received three single-triple capsules q.i.d. and omeprazole, 20 mg b.d., for 10 days. Each capsule contained bismuth biskalcitrate, 140 mg (as 40 mg Bi2O3 equivalent), metronidazole, 125 mg, and tetracycline, 125 mg. 13C-Urea breath test was repeated at least 4 and 8 weeks post-treatment.
  
  
  RESULTS
  Overall eradication rates were 93% (158/170) by modified intention-to-treat analysis and 97% (142/146) by per protocol analysis. Eradication rates were 93% (40/43) and 95% (38/40) for strains resistant to metronidazole and 95% (82/86) and 99% (75/76) for strains sensitive to metronidazole by modified intention-to-treat and per protocol analysis, respectively.
  
  
  CONCLUSIONS
  This omeprazole-bismuth biskalcitrate-metronidazole-tetracycline 10-day regimen is a very effective and well-tolerated treatment, which overcomes metronidazole resistance.
authors.affiliation: Department of Gastroenterology, Adelaide & Health Hospital, Tallaght, Dublin, Ireland. comgast@indigo.ie
authors.forename: C
authors.initials: C
authors.lastname: O'Morain
authors.forename: T
authors.initials: T
authors.lastname: Borody
authors.forename: A
authors.initials: A
authors.lastname: Farley
authors.forename: W A
authors.initials: WA
authors.lastname: De Boer
authors.forename: C
authors.initials: C
authors.lastname: Dallaire
authors.forename: R
authors.initials: R
authors.lastname: Schuman
authors.forename: J
authors.initials: J
authors.lastname: Piotrowski
authors.forename: C A
authors.initials: CA
authors.lastname: Fallone
authors.forename: G
authors.initials: G
authors.lastname: Tytgat
authors.forename: F
authors.initials: F
authors.lastname: Mégraud
authors.forename: J
authors.initials: J
authors.lastname: Spénard
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000863:Antacids / Q000008:administration & dosage* / Q000009:adverse effects; D000900:Anti-Bacterial Agents / Q000008:administration & dosage* / Q000009:adverse effects; D001729:Bismuth / Q000008:administration & dosage* / Q000009:adverse effects; D002214:Capsules; D004338:Drug Combinations; D005260:Female; D016481:Helicobacter Infections / Q000188:drug therapy*; D016480:Helicobacter pylori; D006801:Humans; D008297:Male; D008795:Metronidazole / Q000008:administration & dosage* / Q000009:adverse effects; D008875:Middle Aged; D013752:Tetracycline / Q000008:administration & dosage* / Q000009:adverse effects; D016896:Treatment Outcome
chemical_list: D000863:Antacids; D000900:Anti-Bacterial Agents; D002214:Capsules; D004338:Drug Combinations; D008795:Metronidazole; D013752:Tetracycline; D001729:Bismuth